Page 1 of 7

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

DIN 0 6 F

Substitute for form 1449A-B/PTQ

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known
Application Number	10/003,496
Filing Date	Nov. mber 1, 2001
First Named Inventor	Torb n Lauesgaard Niss n
Group Art Unit	1645 1646n
Examiner Name	Unassign of Jema Ment
Attorney Docket Number	0218us210

	U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	U.S. Patent De Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal				
					RE	CEIVED				
					JUI	1 1 2002				
					TECH CE	NTER 1600/2900				

				FOREIGI	N PATENT DOCUMEN	TS		
		F	oreign Patent Docu	ment		Date of Publication	Pages, Columns, Lines,	T
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
								Г
								<del>                                     </del>

	0:1-	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	T
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
PM	AA	DELGADO, CRISTINA, et al., "The Uses and Properties of PEG-Linked Proteins" Critical Reviews in Therapeutic Drug Carrier Systems 9 (3, 4): 249-304 (1992)	
	АВ	YOUNG, DENNIS C., et al., "Characterization of the receptor binding determinants of granulocyte colony stimulating factor" <i>Protein Science</i> (1997), 6:1228-1236	

Examiner	$\sim 1$	Date	i	1
Signature	I HUM MUM	Considered	9/2	
J.g		Considered	<u> </u>	7 10 9

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 2 0 2002

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for for 1449A-B/PTO

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known
Application Number	10/003,496
Filing Date	N vemb r 1, 2001
First Named Inventor	Torb n Lauesgaard Nissen
Group Art Unit	1645 16 6
Examiner Name	Unassigned Fremer Henry
Attorney Docket Number	0218us210

	U.S. PATENT DOCUMENTS										
Examiner Initials	Cite No.	U.S. Patent Do Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, lines, Where Relevant Passages					
- maaid	140.		(if known)		MM-DD-YYYY	or Relevant Figures Appea					
<del></del>											
_											
						]					
Ì											
			<del>                                     </del>								
		-									
			1 1								

			F! D. ( - ( D.	FOREIGI	N PATENT DOCUMEN			
Examiner Initials	Cite No.	Office	Foreign Patent Doc	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
PM	1	EP	0 783 003	A1	Kyowa Hakko Kogyo Co., Ltd.	07/09/1997	ç	
	2	wo	94/17185	A1	Amgen Inc.	08/04/1994		$\dagger$
	3	wo	96/05224	A1	Washington University	02/22/1996		
$ \forall$	4	wo	96/40772	A2	Johnson & Johnson	12/19/1996		
				<del>  </del>				L

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	1.7
5	Francis, G.E., et al., "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques," <i>International Journal of Hematology</i> , 68(1):1-18 (1998)	
_	No.	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Francis, G.E., et al., "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques." International Journal of

Considered   1   1   1   1	Examiner Signature	Prema Mente	Date Considered	2	131	 04	
----------------------------	-----------------------	-------------	--------------------	---	-----	--------	--

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO Complete if Known Application Number 10/003,496 **ENFORMATION DISCLOSURE** Filing Date STATEMENT BY APPLICANT **November 1, 2001** First Named Inventor Torben Lauesgaard Nissen Group Art Unit 1645 **Examiner Name** use as many sheets as necessary) Unassigned Attorney Docket Number 0218us210

Ó

FEB

PADEN			U.	S. PATENT DOCUME	NTS	· · · · · · · · · · · · · · · · · · ·		
		U.S. Patent Do	cument	Name of Patentee or Applica		. Date of Publication	on of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document		Cited Documer MM-DD-YYYY		Where Relevant Passages or Relevant Figures Appeal
PM	1	4,810,643		Souza		03/06/1989		of Nelevant Figures Appeal
	2	4,833,127		Ono et al.		05/23/1989		
	3	4,904,584		Shaw		02/27/1990		
	4	4,999,291		Souza		03/12/1991		
	5	5,214,132		Kuga et al.		05/25/1993		
	6	5,218,092		Sasaki <i>et al.</i>		06/08/1993		
	7	5,218,093		Guo et al.		06/08/1993		
	8	5,281,698		Nitecki		01/25/1994		
	9	5,316,921		Godowski <i>et al.</i>		05/31/1994		
	10	5,320,840		Camble et al.		06/14/1994	<u>f</u>	
	11	5,349,052		Delgado et al.		09/20/1994		
	12	5,362,853		Kuga <i>et al.</i>		11/08/1994		
	13	5,399,345		Schumacher et al.		03/21/1995		
	14	5,416,195		Camble et al.		05/16/1995		
	15	5,476,653		Pitt et al.		12/19/1995		
	16	5,547,856		Godowski et al.	***	08/20/1996		
	17	5,580,755		Souza		12/03/1996		
	18	5,580,963		Godowski et al.		12/03/1996		
	19	5,581,476		Osslund		12/03/1996		
	20	5,582,823		Souza		12/10/1996		
	21	5,589,456		Smith et al.		12/31/1996		
	22	5,676,941		Souza		10/14/1997		
	23	5,681,720		Kuga <i>et al.</i>		10/28/1997		
	24	5,684,136		Godowski		11/04/1997		
	25	5,763,584		Godowski		06/09/1998		
	26	5,770,704		Godowski		06/23/1998		
	27	5,773,581		Camble et al.		06/30/1998		
Examine Signature		Frema M	ient		Date	sidered 2	/31	104

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO Complete if Known **Application Number** 10/003,496 NFORMATION DISCLOSURE Filing Date November 1, 2001 STATEMENT BY APPLICANT First Named Inventor Torben Lauesgaard Nissen 9 2002 Group Art Unit 1645 Jely 6 use as many sheets as necessary) Examiner Name <del>Unassigned</del> Attorney Docket Number 0218us210

FEB

ĪR	ADEMARY			U.	S. PATENT DOCUMENTS		
	Examiner Initials	Cite No.	U.S. Patent Doo Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	- bW	28	5,790,421		Osslund	08/04/1998	S. Association of the second o
		29	5,795,968		Kuga et al.	08/18/1998	
		30	5,824,778		Ishikawa et al.	10/20/1998	
		31	5,824,784		Kinstler et al.	10/20/1998	
		32	5,830,705		Souza	11/03/1998	
		33	5,880,255		Delgado et al.	03/09/1999	
		34	5,985,263		Lee et al.	11/16/1999	
		35	6,004,548		Souza	12/21/1999	
		36	6,027,720		Kuga et al.	02/22/2000	
		37	6,100,070		Zurfluh et al.	08/08/2000	
		38	6,166,183		Ishikawa et al.	12/26/2000	
		39	6,187,564		Sytkowski	02/13/2001	
		40	6,242,570		Sytkowski	06/05/2001	

		,		FOREIG	N PATENT DOCUMEN	TS		
Examiner Initials	Cite No.	Office	Foreign Patent Doc	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
PM	41	EP	0 256 843	A1	Cetus Corporation	02/24/1988	er vise izan i geree i ppedi	1
	42	EP	0 335 423	A2	Kyowa Hakko Kogyo Co., Ltd.	10/04/1989		_
	43	EP	0 215 126	B1	Chugai Seiyaku Kabushiki Kaisha	07/31/1991		
	44	EP	0 220 520	B1	Chugai Seiyaku Kabushiki Kaisha	09/18/1991		
	45	EP	0 344 796	B1	Chugai Seiyaku Kabushiki Kaisha	09/21/1994		
	46	EP	0 230 980	B2	Chugai Seiyaku Kabushiki Kaisha	03/20/1996		
$\sqrt{}$	47	EP	0 744 409	A1	Kyowa Hakko Kogyo Kabushiki Kaisha	11/27/1996		

[ Francis and					
Examiner	( ) ( ) ( ) ( ) ( ) ( )	Date	7	1	
Signature	L. Firmer Minh	Considered	12/3	104	,
			1 1 3		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Complete if Known Substitute for form 1449A-B/PTO Complete if Known **Application Number** 10/003,496 NFORMATION DISCLOSURE Filing Date November 1, 2001 ATEMENT BY APPLICANT First Named Inventor Torben Lauesgaard Nissen Group Art Unit 1645 1646 FEB 1 B 2002 Examiner Name Unassigned (use as many sheets as necessary) Attorney Docket Number 0218us210

ADEMARY						<u> </u>		
ADEMO	-, -			FOREIG	N PATENT DOCUMEN			
Examiner Initials	Cite No.	Office	Foreign Patent Docu	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
PM	48	EP	0 370 205	B1	Kyowa Hakko Kogyo Co., Ltd.	07/22/1998		
	49	EP	0 921 131	A1	Kyowa Hakko Kogyo Co., Ltd.	06/09/1999		
	50	EP	0 237 545	B2	Kirin-Amgen, Inc.	08/25/1999		1
	51	EP	0 169 566	B2	Chugai Seiyaku Kabushiki Kaisha	07/12/2000		
	52	EP.	0 612 846	B1	Amgen, Inc.	08/16/2000		1
	53	wo	89/05824		Genetics Institute, Inc.	06/29/1989		
	54	wo	89/10932		Amgen, Inc.	11/16/1989		<u> </u>
	55	wo	90/12874		Genetics Institute, Inc.	11/01/1990		
	56	wo	91/05798		Amgen Inc.	05/02/1991		
	57	wo	92/06116		Ortho Pharmaceutical Corporation	04/16/1992		
	58	wo	94/20069		Amgen Center	09/15/1994		
	59	wo	96/11953		Amgen Inc.	04/25/1995		
	60	wo	95/21629		Amgen Inc.	08/17/1995		
	61	wo	97/12977		G.D. Searle & Co.	04/10/1997		
	62	wo	98/27230		Maxygen, Inc.	06/25/1998		
	63	wo	98/53072		Korea Research Institute of Bioscience and Biotechnology <i>et al.</i>	11/26/1998		
	64	wo	99/02710		Beth Israel Deaconess Medical Center	01/21/1999		
	65	wo	99/03887		Bolder Biotechnology, Inc.	01/28/1999		

<b>5</b>				
Examiner	Date		. ,	
Signature	Considered	1 2/3	104	
	Considered		1	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Gof 7

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO	C	omplete if Known
	Application Number	10/003,496
INFORMATION DISCLOSURE	Filing Date	November 1, 2001
P ESTATEMENT BY APPLICANT	First Named Inventor	Torben Lauesgaard Nissen
%)	Group Art Unit	1645 16100
9 2002 se as many sheets as necessary)	Examiner Name	Unassigned from Mins
(pad as many sheets as necessary)	Attorney Docket Number	0218us210
S1		<del>*</del>

ı	- 40	<del>}</del>			FORFIG	N PATENT DOCUMEN	TO		
TR.	DEMARK Examine Initials	r Cite No.	Office	Foreign Patent Docu	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	PM	66	wo	99/38891		Beth Israel Deaconess Medical Center	08/05/1999	дистирист	
		67	wo	99/67291		Immunex Corporation	12/29/1999		
		68	wo	00/17336		Lee	03/20/2000		一
L		69	wo	00/40728		Xencor, Inc.	07/13/2000		
		70	wo	00/44785		Hoffman-La Roche Inc.	08/03/2000		
		71	wo	01/03737	A1	Bolder Biotechnology Inc.	01/18/2001		
	1	72	wo	01/51510	A2	Maxygen ApS	07/19/2001		$\dashv$

	,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
FM	73	ARITOMI, MASAHARU, et al., "Atomic structure of the GCSF-receptor complex showing a new cytokine—receptor recognition scheme," Nature 401:713-717 (1999)	
	74	BOWEN, SHARON, et al., "Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein," Experimental Hematology 27:425-432 (1999)	
	75	HILL, CHRISTOPHER P., et al., "The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors," <i>Proc. Natl. Acad. Sci. USA</i> 90:5167-5171 (1993)	
	76	HORAN, TOM, et al., "Dimerization of Extracellular Domain of Granulocyte-Colony Stimulating Factor Receptor by Ligand Binding: A Monovalent Ligand Induces 2:2 Complexes," Biochemistry 35:4886-4896 (1996)	
	77	LANDAR, AIMEE, et al., "Design, Characterization, and Structure of a Boilogically Active Single-chain Mutant of Human IFN-γ," J. Mol. Biol. 299:169-179 (2000)	

Evorsiner	<del></del>				
Examiner	0.	Mint	Date		,
Signature	reme	menz	Considered	1.2/3	In H
		<del></del>	Considered		<del></del>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO	C	omplete if Known
135	Application Number	10/003,496
O PINFORMATION DISCLOSURE	Filing Date	November 1, 2001
STAPEMENT BY APPLICANT	First Named Inventor	Torben Lauesgaard Nissen
FEB 1 9 2002 🖏	Group Art Unit	1645
-	Examiner Name	Unassigned Prema Ment
(use as many sheets as necessary)	Attorney Docket Number	0218us210

PADEMARY	Z	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
PM	78	LEONG, STEVEN R., et al., "IL-8 single-chain homodimers and heterodimers: Interactions with the chemokine receptors CXCR1, CXCR2, and DARC," Protein Science 6:609-619 (1997)	•
	79	LI, JUN, et al., "Mutants of Single Chain Interleukin 5 Show Asymmetric Recruitment of Receptor α and β <sub>c</sub> Subunits," J. Biol. Chem. 271(49):31729-31735 (1996)	
	80	LI, JUN, et al., "Single Chain Human Interleukin 5 and Its Asymmetric Mutagenesis for Mapping Receptor Binding Sites," J. Biol. Chem. 271(4):1817-1820 (1996)	
	81	NAGATA, SHIGEKAZU, et al., "Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor," Nature 319:415-418 (1986)	
	82	PAIGE, AIMEE G., et al., "Prolonged Circulation of Recombinant Human Granulocyte-Colony Stimulating Factor by Covalent linkage to Albumin Through a Heterobifunctional Polyethylene Glycol," <i>Pharm. Res.</i> 12(12):1883-1888 (1995)	
	83	RANDAL, M., et al., "Crystalization and preliminary X-ray analysis of a 1:1 complex between a designed monomeric interferon-gamma and its soluble receptor," Protein Sci. 7:1057-1060 (1998)	
	84	REIDHAAR-OLSON, John F., et al., "Identification of Residues Critical to the Activity of Human Granulocyte Colony-Stimulating Factor," <i>Biochemistry</i> 35:9034-9041 (1996)	
	85	SATAKE-ISHIKAWA, R., et al., "Chemical Modification of Recombinant Human Granulocyte Colony-Stimulating Factor by Polyethylene Glycol Increases its Biological Activity in vivo," Cell Structure and Function 17:157-160 (1992)	
On the little of	86	SOUZA, LAWRENCE M., et al., "Recombinant Human Granulocyte Colony- Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells," Science 232:61-65 (1986)	
The state of the s	87	YAMASAKI, M., et al., "Effect of Divalent Polyethylene Glycol Units, Conjugated on Human Granulocyte Colony-Stimulating Factor, on Biological Activities In Vitro and In Vivo," Drugs Exptl. Clin. Res. 24(4):191-196 (1998)	
	88	ZINK, THOMAS, et al., "Structure and Dynamics of the Human Granulocyte Colony- Stimulating Factor Determined by NMR Spectroscopy. Loop Mobility in a Four- Helix-Bundle Protein," <i>Biochemistry</i> 33:8453-8463 (1994)	
Examine Signature	-	Prema Ments Date Considered 2/3/04	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.